Results 11 to 20 of about 689,752 (349)
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma [PDF]
International Journal of Molecular Sciences, 2021 Lung cancer is one of the most common malignant neoplasms. As a result of the disease’s progression, patients may develop metastases to the central nervous system. The prognosis in this location is unfavorable; untreated metastatic lesions may lead to death within one to two months.
Agnieszka Rybarczyk-Kasiuchnicz +2 more
openaire +3 more sources
Cetuximab and biomarkers in non-small-cell lung carcinoma
Biologics: Targets and Therapy, 2012 Cancer progression is a highly complex process that is driven by a constellation of deregulated signaling pathways and key molecular events. In non-small-cell lung cancer (NSCLC), as in several other cancer types, the epidermal growth factor receptor (EGFR) and its downstream signaling components represent a key axis that has been found not only to ...
Nitin Patil +2 more
openaire +6 more sources
Targeted therapy of non-small-cell lung carcinoma [PDF]
Therapeutic Advances in Respiratory Disease, 2011 The rapid expansion of novel technologies in cancer research over the past several years has led to a dramatically improved understanding of the molecular biology of lung cancer. As a consequence, novel targeted therapies are rapidly being developed.
Seth A. Brodie +2 more
openaire +4 more sources
Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors [PDF]
International Journal of Cancer, 2017 Availability of lung cancer models that closely mimic human tumors remains a significant gap in cancer research, as tumor cell lines and mouse models may not recapitulate the spectrum of lung cancer heterogeneity seen in patients. We aimed to establish a
Balbin +48 more
core +2 more sources
Cemiplimab for cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer. [PDF]
Aust Prescr, 2022 europepmc +2 more sources
Durvalumab for urothelial carcinoma, non-small cell lung cancer. [PDF]
Aust Prescr, 2019 europepmc +2 more sources
Epigenetics in non-small cell lung carcinomas [PDF]
Salud Pública de México, 2019 Objective. To perform a systematic review of the main epigenetic aberrations involved in non-small cell lung carcinomas’ (NSCLC) diagnosis, progression, and therapeutics. Materials and methods. We performed a systematic review of the scientific literature on lung cancer epigenetics, focusing on NSCLC. Results.
Federico Ávila-Moreno +3 more
openaire +3 more sources
Lung Cancer: A Literature Review
Jurnal Respirasi, 2023 Lung cancer is a cancer whose onset starts in the lungs where there is an abnormal cell growth that is very fast and uncontrolled. The abnormal cell growth is triggered by deoxyribonucleic acid (DNA) damage, including deletions in the DNA section ...
Yan Efrata Sembiring +8 more
doaj +1 more source
Lung: Non-small cell carcinoma [PDF]
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011 Non-small cell carcinomas are divided into three main categories according to the predominant morphology of the tumour cells as determined by light microscopy. Although it is possible to distinguish different histological sub-groups in this way, or by using gene expression profiling, treatment is currently decided on the basis of tumour staging, age ...
J Heighway, DC Betticher
openaire +2 more sources
Thoracic Cancer, 2021 Immune checkpoint inhibitors with chemotherapy have been shown to exhibit remarkable efficacy for advanced non‐small‐cell lung carcinoma and are under investigation as an induction therapy.
Shunichi Saito +6 more
doaj +1 more source